Other languages BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX Other stock markets 03:08:41 2024-04-26 pm EDT			5-day change	1st Jan Change
2.505 ^USD	+11.33%		+17.58%	+0.61%

Mar. 27	HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating	MT
Mar. 26	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 26
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	Dec. 21
Sector Update: Health Care Stocks Advance in Afternoon Trading	Dec. 21
BioAtla Rallies After CEO Buys 50,000 Shares	Dec. 21
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	Dec. 13
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	Dec. 05
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	Dec. 05
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	Dec. 05
Top Premarket Decliners	Nov. 27
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
Top Premarket Decliners	23-05-08
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit	23-02-27
BioAtla President Scott Smith to Leave; Appointed as CEO at Viatris	23-02-27
Bioatla, Inc. Announces Resignation of Scott Smith as President	23-02-27
BioAtla Says US FDA Approves Investigational New Drug Application for BA3182 to Treat Adenocarcinoma	23-02-23
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3182, A Cab Epcamxcab-Cd3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma	23-02-23
BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer This Quarter	23-01-10
BioAtla Proposes Common Stock Offering of up to $100 Million	23-01-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioAtla, Inc.

Equities

BCAB

US09077B1044

Other languages

Filters